{
    "ticker": "ONCY",
    "name": "OncoCyte Corporation",
    "description": "OncoCyte Corporation is a biotechnology company focused on the development and commercialization of innovative cancer diagnostics. Founded in 2014 and based in Alameda, California, OncoCyte aims to provide solutions that enhance the detection and monitoring of cancer, thereby improving patient outcomes. The company's lead product, DetermaRx, is a novel diagnostic test designed to predict the risk of recurrence in patients with early-stage lung cancer, allowing for more personalized treatment decisions. OncoCyte\u2019s proprietary platform leverages advancements in genomic and proteomic technologies to identify specific biomarkers associated with various cancer types. This enables healthcare providers to make informed decisions based on a patient\u2019s unique cancer profile. With a commitment to advancing precision medicine, OncoCyte is dedicated to transforming the landscape of oncology diagnostics through ongoing research and development. The company is actively pursuing additional diagnostic tests for other cancer types, including breast and bladder cancer, to further expand its product offerings and market reach. OncoCyte collaborates with leading research institutions and healthcare organizations to validate its tests and promote their adoption in clinical practice, ultimately striving to reduce the burden of cancer through early and accurate detection.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Alameda, California, USA",
    "founded": "2014",
    "website": "https://www.oncocyte.com",
    "ceo": "Ron Andrews",
    "social_media": {
        "twitter": "https://twitter.com/OncoCyte",
        "linkedin": "https://www.linkedin.com/company/oncocyte/"
    },
    "investor_relations": "https://investors.oncocyte.com",
    "key_executives": [
        {
            "name": "Ron Andrews",
            "position": "CEO"
        },
        {
            "name": "Michael N. Egholm",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Diagnostics",
            "products": [
                "DetermaRx"
            ]
        }
    ],
    "seo": {
        "meta_title": "OncoCyte Corporation | Innovative Cancer Diagnostics",
        "meta_description": "OncoCyte Corporation specializes in advanced cancer diagnostics, providing innovative solutions like DetermaRx to predict cancer recurrence and improve patient outcomes.",
        "keywords": [
            "OncoCyte",
            "Cancer Diagnostics",
            "DetermaRx",
            "Biotechnology",
            "Precision Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is OncoCyte known for?",
            "answer": "OncoCyte is known for its innovative cancer diagnostics, particularly the DetermaRx test for lung cancer."
        },
        {
            "question": "Who is the CEO of OncoCyte?",
            "answer": "Ron Andrews is the CEO of OncoCyte Corporation."
        },
        {
            "question": "Where is OncoCyte headquartered?",
            "answer": "OncoCyte is headquartered in Alameda, California, USA."
        },
        {
            "question": "What are OncoCyte's main products?",
            "answer": "OncoCyte's main product is DetermaRx, a diagnostic test for lung cancer."
        },
        {
            "question": "When was OncoCyte founded?",
            "answer": "OncoCyte was founded in 2014."
        }
    ],
    "competitors": [
        "EXAS",
        "NTRA",
        "MDGL"
    ],
    "related_stocks": [
        "ABT",
        "BMY",
        "GILD",
        "AMGN"
    ]
}